Presenter: JM Ferrero Presenter's Affiliation: GINECO, Paris, France Type of Session: Poster
Previous studies have demonstrated that patients with ovarian cancer who have a time-to-relapse interval > 6 months retain sensitivity to platinum-derivatives
Caelyx (Ca, doxil) is a liposomal doxorubicin that has been shown to be as effective as topotecan in ovarian cancer patients in relapse after a platinum-based regimen
A previous phase I study by P. Viens determined the safe doses of a regimen consisting of Caelyx (Ca, 30 mg/m2 on day 1) and carboplatin (Pa, 30 minute infusion of AUC 5 mg/ml per minute on day 1) delivered every 4 weeks
The GINECO initiated a phase II trial to investigate the efficacy and tolerance of combined Ca and Pa in ovarian cancer patients with late relapse (> 6 months) who were pre-treated with platinum and taxane based chemotherapy.
Materials and Methods
The study was an open, non comparative, multicentre, phase II trial
Eligibility criteria included recurrent ovarian carcinoma previously treated with one or two platinum and taxane based regimes with a treatment-free interval between last treatment and inclusion of > 6 months,
From 04/00 to 03/01, 105 patients were treated with a regimen consisting of Ca, 30 mg/m2 on day 1, and Pa, AUC 5 mg/ml per minute for 30 minutes on day 1, repeated on day 28
Response was evaluated every two cycles using WHO criteria for measurable disease and Rustin?s criteria for non-measurable disease and CA-125 > 40IU/ml
The median age was 61 years (range 23-79)
Histology was serous in 74% with Grade as follows; Grade 1-2, 31%; grade 3, 26%; unknown grade, 43%
54% had measurable disease, and 86% had a CA-125 > 40 IU/ml
Previously treated with 1 regimen, 60%; with 2, 40%
Nov 21, 2012 - A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer, according to research published in the Oct. 1 issue of Clinical Cancer Research.